-+ 0.00%
-+ 0.00%
-+ 0.00%

OraSure Submits Two Separate Applications At 2025 End To FDA For Clearance Of Rapid Molecular Self-Test For CT/NG As Well As Colli-Pee At-Home Urine Collection Device For STIs

Benzinga·01/05/2026 13:04:38
Listen to the news

OraSure Technologies, Inc. (NASDAQ:OSUR) ("OraSure" and "OTI"), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that it submitted two separate applications at the end of 2025 to the U.S. Food and Drug Administration (FDA) for clearance of its rapid molecular self-test for Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG) as well as its Colli-Pee™ at-home urine collection device for sexually transmitted infections (STIs).